Select Page

The technologies in cancer biomarker has undergone significant change in recent years, with Bence-Jones protein based cancer biomarker to genomic profiling technologies based cancer biomarker. The rising wave of new technologies such as omics and bioinformatics are creating significant potential for advanced cancer biomarker in various medical platforms due to its feature of carefully addressing the heterogeneity issues.
To download report brochure, please go to https://www.lucintel.com/technology-cancer-biomarker-market.aspx and click “report brochure” tab from the menu.
In cancer biomarker market, various technologies such as omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics technologies are used in the diagnostics, research and development, prognostics, and risk assessment applications. Rising incidence of cancer, increasing use of cancer biomarkers in drug discovery and development, and growing research on cancer biomarkers are creating new opportunities for various cancer biomarkers technologies.
Lucintel, a leading global management consulting and market research firm with over 1,000 clients worldwide, has analyzed the technologies used in cancer biomarker market and it has now published a comprehensive research report titled “Technology Landscape, Trends and Opportunities in the Global Cancer Biomarker Market”. This report analyzes technology maturity, degree of disruption, competitive intensity, market potential and other parameters of various technologies in cancer biomarker market.
Lucintel study finds that cancer biomarkers technology is forecast to grow at 13% during next five years. Omics technology is the largest segment of this market. Roche, Abbott Laboratories, GlaxoSmithKline, Novartis, Pfizer, and Qiagen are among the major players in the cancer biomarker market.
The Lucintel report serves as a catalyst for growth as it provides a comprehensive data and analysis on trends, key drivers, and directions. The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global cancer biomarkers technology by technology, application, and region as follows:
Technology Readiness by Technology Type
Competitive Intensity and Regulatory Compliance
Disruption Potential by Technology Type
Trends and Forecasts by Technology [$M shipment analysis from 2013 to 2024]:
• Omics Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics
• Bioinformatics
Technology Trends and Forecasts by Application [$M shipment analysis from 2013 to 2024]:
• Diagnostics
o Omics Technologies
o Imaging Technologies
o Immunoassays
o Cytogenetics
o Bioinformatics
• Research and Development
o Omics Technologies
o Imaging Technologies
o Immunoassays
o Cytogenetics
o Bioinformatics
• Prognostics
o Omics Technologies
o Imaging Technologies
o Immunoassays
o Cytogenetics
o Bioinformatics
• Risk Assessment
o Omics Technologies
o Imaging Technologies
o Immunoassays
o Cytogenetics
o Bioinformatics
• Others
Technology trends and Forecasts by Region [$M shipment analysis for 2013 to 2024]:
• North America
– United States
– Canada
– Mexico
• Europe
– United Kingdom
– Germany
– France
• Asia Pacific
– Japan
– China
– South Korea
– India
• The Rest of the World
Latest Developments and Innovations in the Cancer Biomarker Technologies
Companies / Ecosystems
Strategic Opportunities by Technology Type
A more than 150-pages of research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/technology-cancer-biomarker-market.aspx or helpdesk@lucintel.com. Lucintel offerings include Medical Market Analysis, Medical Market Research, Market Research Report, Capital Investment Feasibility and SWOT Analysis.